Enhancing endothelial progenitor cell for clinical use |
| |
Authors: | Lei Ye Kian-Keong Poh |
| |
Institution: | Lei Ye, National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, SingaporeKian-Keong Poh, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, SingaporeKian-Keong Poh, Department of Cardiology, National University Heart Center, National University Health System, Singapore 119228, Singapore |
| |
Abstract: | Circulating endothelial progenitor cells (EPCs) have been demonstrated to correlate negatively with vascular endothelial dysfunction and cardiovascular risk factors. However, translation of basic research into the clinical practice has been limited by the lack of unambiguous and consistent definitions of EPCs and reduced EPC cell number and function in subjects requiring them for clinical use. This article critically reviews the definition of EPCs based on commonly used protocols, their value as a biomarker of cardiovascular risk factor in subjects with cardiovascular disease, and strategies to enhance EPCs for treatment of ischemic diseases. |
| |
Keywords: | Endothelial progenitor cells Cell therapy Enhancing function and number CD34 Clinical trials |
|
| 点击此处可从《World journal of stem cells》浏览原始摘要信息 |
|